Search results for " Mal"

showing 10 items of 5318 documents

BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases

2008

Male breast cancer (MBC) is a rare and poorly known disease. Germ-line mutations of BRCA2 and, to lesser extent, BRCA1 genes are the highest risk factors associated with MBC. Interestingly, BRCA2 germ-line rearrangements have been described in high-risk breast/ovarian cancer families which included at least one MBC case. Germ-line mutations of CHEK2 gene have been also implicated in inherited MBC predisposition. The CHEK2 1100delC mutation has been shown to increase the risk of breast cancer in men lacking BRCA1/BRCA2 mutations. Intriguingly, two other CHEK2 mutations (IVS2+1G>A and I157T) and a CHEK2 large genomic deletion (del9-10) have been associated with an elevated risk for prostate c…

AdultMaleCancer Researchendocrine system diseasesGenes BRCA2Genes BRCA1male breast cancerProtein Serine-Threonine KinasesBiologychek2medicine.disease_causeBreast Neoplasms Malebrca1Breast cancerbrca2medicineHumansBRCA1/BRCA2germ-line mutationsMultiplex ligation-dependent probe amplificationmlpaskin and connective tissue diseasesneoplasmsCHEK2Germ-Line MutationGene RearrangementMutationCancerGene rearrangementmedicine.diseaseCheckpoint Kinase 2Oncologylarge genomic rearrangementsMale breast cancerCancer researchbrca1; brca2; chek2; germ-line mutations; large genomic rearrangements; male breast cancer; mlpaBreast diseaseBreast Cancer Research and Treatment
researchProduct

The heterogeneity of changes in incidence and survival among lymphoid malignancies in a 30-year French population-based registry.

2014

Our specialized population-based registry has allowed us to explore changes in incidence and survival by subtype over the last 30 years. Between 1980 and 2009, 4790 cases of lymphoid malignancies were registered using the International Classification of Diseases for Oncology. The incidence rate of lymphoid malignancies was 20.5 per 100,000 inhabitants per year, and ranged from 0.1 to 4 according to subtype. Five-year net survival was 65%, and ranged from 41% to 93% according to subtype. We observed an increase in 5-year net survival between the periods 1980-1989 and 2000-2009 (58% vs. 70%). This was observed in most but not all subtypes. Our long-standing population-based registry allowed u…

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentLymphomaPopulationYoung AdultSurvival probabilityInternal medicinemedicineHumansRegistrieseducationChildNet SurvivalAgedAged 80 and overeducation.field_of_studyLeukemiabusiness.industryIncidence (epidemiology)IncidenceHematologyMiddle AgedSurvival AnalysisCancer registryOncologyLymphoid malignancyChild PreschoolHematologic NeoplasmsPopulation SurveillanceImmunologyFemaleFrancebusinessPopulation-Based RegistryInternational Classification of Diseases for OncologyFollow-Up StudiesLeukemialymphoma
researchProduct

Cardiovascular Risk in Polycythemia Vera: Thrombotic Risk and Survival: Can Cytoreductive Therapy Be Useful in Patients with Low-Risk Polycythemia Ve…

2019

<b><i>Background/Aims:</i></b> Cardiovascular risk factors are not considered in the current scores for evaluation of the thrombotic risk in myeloproliferative neoplasms, and in polycythemia vera (PV) in particular. Cytoreduction is currently not indicated in low-risk patients with PV, despite the absence or presence of cardiovascular risk factors. Our purpose is to highlight how cardiovascular risk factors in patients with PV increase the thrombotic risk both in low- and high-risk patients. <b><i>Methods:</i></b> We collected and analyzed data from 165 consecutive patients with a diagnosis of PV followed at our institution and compared the fr…

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentPopulationCardiovascular risk factorsKaplan-Meier EstimateSettore MED/15 - Malattie Del SangueCytoreductionYoung AdultPolycythemia veraSurvival dataInternal medicinemedicineHumansIn patienteducationAgedRetrospective StudiesAged 80 and overThrombotic riskeducation.field_of_studybusiness.industryThrombosisCytoreduction Surgical ProceduresHematologyMiddle AgedCardiovascular riskmedicine.diseaseThrombosisPolycythemia veraOncologyCardiovascular DiseasesHeart Disease Risk FactorsRisk stratificationFemalebusinessOncology Research and Treatment
researchProduct

Population attributable risk of tobacco and alcohol for upper aerodigestive tract cancer.

2011

Tobacco and alcohol are major risk factors for upper aerodigestive tract (UADT) cancer and significant variation is observed in UADT cancer rates across Europe. We have estimated the proportion of UADT cancer burden explained by tobacco and alcohol and how this varies with the incidence rates across Europe, cancer sub-site, gender and age. This should help estimate the minimum residual burden of other risk factors to UADT cancer, including human papillomavirus. We analysed 1981 UADT cancer cases and 1993 controls from the ARCAGE multicentre study. We estimated the population attributable risk (PAR) of tobacco alone, alcohol alone and their joint effect. Tobacco and alcohol together explaine…

AdultMaleCancer Researchmedicine.medical_specialtyAlcohol DrinkingEsophageal NeoplasmsAlcoholchemistry.chemical_compoundRisk FactorsTobaccomedicineHumansPopulation attributable riskGynecologyMouth neoplasmbusiness.industryIncidenceMedicine (all)Incidence (epidemiology)SmokingCase-control studyCancerAlcohol; ARCAGE study; Population attributable risk; Tobacco; Upper aerodigestive tract cancer; Adult; Alcohol Drinking; Case-Control Studies; Esophageal Neoplasms; Europe; Female; Humans; Incidence; Male; Middle Aged; Mouth Neoplasms; Otorhinolaryngologic Neoplasms; Risk Factors; Smoking; Oral Surgery; Medicine (all); Oncology; Cancer ResearchMiddle Agedmedicine.diseaseUpper aerodigestive tract cancerARCAGE studyEuropeOtorhinolaryngologic NeoplasmsUpper aerodigestive tractOncologychemistryCase-Control StudiesAttributable riskFemaleMouth NeoplasmsUpper aerodigestive tract cancer; ARCAGE study; Population attributable risk; Tobacco; AlcoholOral SurgeryAlcoholbusinessOropharyngeal CancersDemography
researchProduct

Does access to care play a role in liver cancer survival? The ten-year (2006–2015) experience from a population-based cancer registry in Southern Ita…

2021

Abstract Background Hepatocellular carcinoma (HCC) is the most frequent primary invasive cancer of the liver. During the last decade, the epidemiology of HCC has been continuously changing in developed countries, due to more effective primary prevention and to successful treatment of virus-related liver diseases. The study aims to examine survival by level of access to care in patients with HCC, for all patients combined and by age. Methods We included 2018 adult patients (15–99 years) diagnosed with a primary liver tumour, registered in the Palermo Province Cancer Registry during 2006–2015, and followed-up to 30 October 2019. We obtained a proxy measure of access to care by linking each re…

AdultMaleCancer Researchmedicine.medical_specialtyCarcinoma HepatocellularAdolescentContext (language use)access to care cancer registries liver cancer public health survival Adolescent AdultAge Distribution Aged Aged 80 and over Carcinoma Hepatocellular Decision Making Organizational Decision Support Techniques Female Follow-Up Studies Health Services Accessibility Health Services Needs and Demand Humans Italy Liver Neoplasms Male Middle Aged Registries Survival Analysis Young AdultSettore MED/42 - Igiene Generale E Applicatalcsh:RC254-282survivalHealth Services AccessibilityDecision Support Techniquesliver cancerYoung AdultAge DistributionInternal medicineHealth careEpidemiologyGeneticsmedicineHumansRegistriesDecision Making OrganizationalAgedAged 80 and overaccess to careHealth Services Needs and Demandbusiness.industryPublic healthLiver Neoplasmspublic healthMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseSurvival AnalysisCancer registryItalyOncologycancer registriesHepatocellular carcinomaAmbulatoryFemaleLiver cancerbusinessFollow-Up StudiesResearch ArticleBMC Cancer
researchProduct

Comparison of Different Nodal Staging in Patients With Locally Advanced Mid-low Rectal Cancer After Long-term Neoadjuvant Chemoradiation Therapy.

2019

Background/Aim: The aim of this study was to compare the ability of different lymph nodal staging systems to predict cancer recurrence in a multicenter European series of patients who underwent proctectomy after neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Patients and Methods: Data on 170 consecutive patients undergoing proctectomy after neoadjuvant therapy for cT3-4 or cN+ rectal adenocarcinoma were retrieved from the European MRI and Rectal Cancer Surgery database. The prognostic role of the number of retrieved and examined nodes, nodal ratio, and log odds of positive lymph nodes (LODDS) was analyzed and compared by receiver operating characteristic curves, Pearson t…

AdultMaleCancer Researchmedicine.medical_specialtyMultivariate analysisColorectal cancerDisease-free survivalmedicine.medical_treatmentLODDSLocally advancedAdenocarcinomaDisease-Free SurvivalLog odds of positive lymph nodeRectal AdenocarcinomaMedicineHumansRectal cancerLog odds of positive lymph nodesNeoadjuvant therapyAgedNeoplasm StagingAged 80 and overReceiver operating characteristicddc:617business.industryRectal NeoplasmsHazard ratioGeneral MedicineNodal ratioChemoradiotherapyMiddle Agedmedicine.diseasePrognosisConfidence intervalNeoadjuvant TherapyOncologydisease-free survival; lodds; log odds of positive lymph nodes; neoadjuvant therapy; nodal ratio; rectal cancer; adenocarcinoma; adult; aged; aged 80 and over; disease-free survival; female; humans; lymph nodes; male; middle aged; neoplasm recurrence Local; Neoplasm Staging; Prognosis; Rectal Neoplasms; Chemoradiotherapy; Neoadjuvant TherapyNeoadjuvant therapyFemaleRadiologyLymph NodesNeoplasm Recurrence LocalbusinessAnticancer research
researchProduct

Salivary flow and xerostomia in patients with type 2 diabetes

2018

Background: Saliva is secreted by the major and minor salivary glands. There are a number of physiological factors that can reduce this secretion such as age, sex, body weight, number of teeth present in the mouth or time of day. This decrease may also be caused by the use of certain drugs, radiotherapy for head and neck cancer, chronic rheumatic diseases such as Sjögren's syndrome and other systemic disorders such as diabetes mellitus (DM). Objective of this study was to investigate the effect of type 2 DM on salivary secretion and its relation to the sensation of xerostomia. Methods: Forty-seven patients with type 2 DM and 46 healthy individuals, aged 40-80, participated in the study. Sam…

AdultMaleCancer Researchmedicine.medical_specialtySalivadiabetes mellitus type 2saliva xerostomia diabetes mellitus type 22734030209 endocrinology & metabolismStimulationType 2 diabetesSalivary GlandsPathology and Forensic MedicineNO03 medical and health sciencessymbols.namesake0302 clinical medicinestomatognathic systemSurveys and QuestionnairesInternal medicineDiabetes mellitusSensationmedicineHumansxerostomiaFisher's exact testAgedAged 80 and overMealsalivabusiness.industryOtorhinolaryngology2734 Pathology and Forensic MedicineHead and neck cancerMED/28 - MALATTIE ODONTOSTOMATOLOGICHE030206 dentistryMiddle Agedmedicine.diseasestomatognathic diseasesDiabetes Mellitus Type 2OtorhinolaryngologysymbolsPeriodonticsFemaleOral Surgerybusiness
researchProduct

Surgery-triggered and non surgery-triggered Bisphosphonate-related Osteonecrosis of the Jaws (BRONJ): A retrospective analysis of 567 cases in an Ita…

2011

Invasive local procedures are often reported in clinical history of patients suffering from Bisphosphonates-Related Osteonecrosis of the Jaws (BRONJ) but over 40% of spontaneous forms have been also described in literature. We compared age, gender, underlying bone disorders, bisphosphonate therapy, clinical features and surgical outcome of 205 cases (36.2%) of BRONJ non surgery-triggered (group 1) with 362 (63.8%) cases of surgery-triggered forms (group 2). Differences between group 1 and 2 were analysed using Mann-Whitney U and χ2 tests. Statistical analysis was performed using STATA 8. Zoledronate was the most used type of bisphosphonate (63.4% versus 69.0%) and the mandible was the most …

AdultMaleCancer Researchmedicine.medical_specialtyTooth extractionmedicine.medical_treatmentZoledronic AcidSettore MED/28 - Malattie OdontostomatologicheRisk FactorsClinical historySpontaneous formmedicineRetrospective analysisHumansStatistical analysisStage (cooking)AgedRetrospective StudiesAged 80 and overSurgical outcomeBone Density Conservation AgentsDiphosphonatesBRONJOrthognathic Surgical Proceduresbusiness.industryImidazolesOsteonecrosisBisphosphonates-related Osteonecrosis of the JawMiddle AgedBisphosphonateSurgeryZoledronic acidItalyOncologyMulticenter studyFemaleBisphosphonate therapyOral SurgerybusinessJaw Diseasesmedicine.drugOral Oncology
researchProduct

Hematopoietic stem-cell transplantation for advanced systemic mastocytosis

2014

Purpose Advanced systemic mastocytosis (SM), a fatal hematopoietic malignancy characterized by drug resistance, has no standard therapy. The effectiveness of allogeneic hematopoietic stem-cell transplantation (alloHCT) in SM remains unknown. Patients and Methods In a global effort to define the value of HCT in SM, 57 patients with the following subtypes of SM were evaluated: SM associated with clonal hematologic non–mast cell disorders (SM-AHNMD; n = 38), mast cell leukemia (MCL; n = 12), and aggressive SM (ASM; n = 7). Median age of patients was 46 years (range, 11 to 67 years). Donors were HLA-identical (n = 34), unrelated (n = 17), umbilical cord blood (n = 2), HLA-haploidentical (n = 1)…

AdultMaleCancer Researchmedicine.medical_specialtyTransplantation ConditioningAdolescentmedicine.medical_treatmentMedizinDrug resistanceHematopoietic stem cell transplantationMastocytosis SystemicInternal medicinemedicineHumansTransplantation HomologousSystemic mastocytosisChildSurvival rateAgedRetrospective StudiesmastocytosisHematologybusiness.industryRemission InductionHematopoietic Stem Cell TransplantationORIGINAL REPORTSMiddle Agedmedicine.diseaseMast cell leukemia3. Good healthSurvival RateTransplantationSettore MED/15 - MALATTIE DEL SANGUEHaematopoiesisTreatment OutcomeOncologyImmunologyCancer researchFemalebusinesstransplantation
researchProduct

Management of venous thromboembolism in patients with acute leukemia at high bleeding risk: a multi-center study

2016

In the last decades, evaluation of clinically relevant thrombotic complications in patients with acute leukemia (AL) has been poorly investigated. The authors performed a multi-center study to evaluate the management of symptomatic venous thromboembolism (VTE) in adult patients with AL. The intention was to find as clinically relevant the following: symptomatic Venous Thrombosis (VT) occurred in typical (lower limbs) and atypical (cerebral, upper limbs, abdominal, etc) sites with or without pulmonary embolism (PE). Over a population of 1461 patients with AL, 22 cases of symptomatic VTE were recorded in hospitalized patients with a mean age of 54.6 years. The absolute incidence of VTE was 1.…

AdultMaleCancer Researchmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentPopulationLow molecular weight heparinHemorrhage030204 cardiovascular system & hematologyYoung Adult03 medical and health sciences0302 clinical medicineVenous thrombosisLow Molecular Weight HeparinHumansMedicineacute leukemiacardiovascular diseaseseducationAgedAged 80 and overVenous ThrombosisAcute leukemiaeducation.field_of_studyAcute leukemiaChemotherapyLeukemiabusiness.industrylow molecular weight heparinIncidenceIncidence (epidemiology)Disease ManagementVenous ThromboembolismHematologyMiddle Agedmedicine.diseasePulmonary embolismSurgeryVenous thrombosisOncology030220 oncology & carcinogenesisAcute DiseaseFemaleacute leukemia; low molecular weight heparin; Venous thrombosisbusinessSettore MED/15 - Malattie del SangueVenous thromboembolismLeukemia & Lymphoma
researchProduct